Analysts expect Onconetix, Inc. to report revenue of 0.00 for Q1 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q4 22, came in at 0.00.
| Metric | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180,299.38 | 220,480.38 | 227,908.59 | 189,372.32 | ||||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167,773.96 | 205,298.80 | 189,322.25 | 175,553.32 | ||||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 174,036.67 | 212,889.59 | 208,615.42 | 182,462.82 |
Analysts expect Onconetix, Inc. to report earnings per share of -33,272.88 for Q3 23, against a range of -35,954.08 to -30,591.68. The most recent reported quarter, Q2 23, came in at -30,600.00, a 59.0% miss against the -19,247.71 consensus.
| Metric | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -45,900.00 | -34,000.00 | -30,600.00 | -30,600.00 | - | - | - | - | - | - | - | - | ||||||||||||||
| High Estimate | - | -42,250.81 | -34,523.31 | -17,920.48 | -30,591.68 | -32,663.50 | -34,664.31 | -32,186.11 | -34,044.78 | -35,756.48 | -42,722.70 | -43,562.23 | ||||||||||||||
| Low Estimate | - | -45,685.43 | -38,063.67 | -20,574.94 | -35,954.08 | -36,934.00 | -42,179.83 | -36,611.73 | -37,448.20 | -41,147.70 | -46,930.38 | -48,729.75 | ||||||||||||||
| Consensus Estimate | - | -43,968.12 | -36,293.49 | -19,247.71 | -33,272.88 | -34,798.75 | -38,422.07 | -34,398.92 | -35,746.49 | -38,452.09 | -44,826.54 | -46,145.99 |